Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ipilimumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Yervoy

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,682

    2019 Revenue in Millions : 1,489

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 2,026

    2020 Revenue in Millions : 1,682

    Growth (%) : 20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 2,131

    2021 Revenue in Millions : 2,026

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 2,238

    2022 Revenue in Millions : 2,131

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol-Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2014 Revenue in Millions : 36.30%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol-Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 1,308

    2014 Revenue in Millions : 1,126

    Growth (%) : -14%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 1,244

    2016 Revenue in Millions : 1,053

    Growth (%) : 18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 1,053

    2015 Revenue in Millions : 1,126

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 1,330

    2017 Revenue in Millions : 1,244

    Growth (%) : 7%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Yervoy

    Ipilimumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Yervoy

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Bristol Myers Squibb/Celgene

    Ipilimumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 1,489

    2018 Revenue in Millions : 1,330

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF